IOBT IO Biotech Inc.: Accounting Value per Share

Graphic logo of IO Biotech (IOBT)

IO Biotech, Inc. (IOBT) minimizes technological threats by developing tools for tumor recognition, while integration with traditional treatment methods expands its audience reach. The company operates in an autonomous cycle independent of global market fluctuations, establishing it as a resilient asset. This chart illustrating the price evolution of the stock confirms the potential of the T-win platform at the value of 0.00, which provides significant pricing power through unique cancer vaccines.

IOBT: IO Biotech Corp Net Asset Value per Share 07/04/2022 - 04/18/2026

iobiotech.com - analytical breakdowns and key metrics (IOBT)

- price and consensus price forecast:
Stock Price IO Biotech Corp|IOBT - Price Target Chart
- market capitalization data:
Market Valuation IO Biotech, Inc.|IOBT - Aggregate Business Value
- book capitalization data:
Net Assets per Single Share IO Biotech|IOBT - Total Stockholders' Equity|Market Value to Book Value Ratio iobiotech.com|IOBT - Total Business Assets
- debt and liquidity data:
Total Debt to Capital IO Biotech, Inc.|IOBT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity IO Biotech|IOBT - Company Cumulative Debt|Debt to Book Capitalization Ratio IO Biotech, Inc.
Fundamental company valuation:IOBT - IO Biotech Corp
Flagship merchandise of IO Biotech

A conservative approach requires assessing the actual net asset value minus liabilities, which allows for the elimination of speculative noise. This calculation determines the intrinsic value of the shareholder's stake, and the book value per share of IO Biotech, Inc. (IOBT) reflects the financial stability of IO Biotech, Inc. (IOBT) amid its dependence on FDA and EMA approvals while funding R&D through partnerships.

Competitor analysis for IO Biotech, Inc.

IBRX - Book Value per Share|Immunocore Corp (IMCR) - Net Assets per Single Share|JANX - Accounting Value per Share|RCUS (arcusbio.com) - Book Price of a Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share sutrobio.com|INKT: Book Value per Share|Book Value of One Share werewolftx.com HOWL|IMMX: Accounting Value per Share|ALXO - Net Asset Value per Share|Accounting Value per Share Cue Biopharma, Inc. (CUE)|PDSB - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx